Identifying and characterizing commercially insured patients with HFpEF with high vs low health care resource utilization
J. Earl, L. A. Hart, and R. N. Hansen
Real-time continuous glucose monitoring vs self-monitoring of blood glucose in distinct multi-ethnic cohorts of patients living with insulin-treated type 2 diabetes in the United States: A cost-utility analysis from a Medicare perspective
H. Alshannaq, J. Matuoka, R. F. Pollock, W. Ahmed, P. Lynch, and G. J. Norman
Ustekinumab infusion to subcutaneous transition: Coordinating care and identifying potential gaps
C. P. Renfro, J. Fann, J. DeClercq, R. D. Baggett, P. Nichols, M. Kozlicki, L. Choi, and A. D. Zuckerman
Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals: An analysis using the Premier Healthcare Database
C. R. Tan, E. Chinaeke, N. Kim, D. Lin, L. Hester, J. Fowler, D. Gifkins, S. Walker, A. Z. Fu, and B. Wu
Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data
F. H. Frech, G. Li, T. R. Juday, Y. Ding, S. Mattke, A. S. Khachaturian, A. S. Rosenberg, C. Ndiba-Markey, A. Rava, R. Batrla, S. De Santi, and H. Hampel
Group-based trajectory modeling to assess adherence to chronic urate-lowering therapies among commercially insured US adults with gout
J. G. Rizk, D. M. Qato, C. O. Bingham, and S. dosReis
Research Brief
Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns
J. F. Merola, S. Welby, H. Roque, J. Song, O. Pilipczuk, C. Lu, and J. A. Walsh
Viewpoint
Will the emerging private-label market access channel help or hinder biosimilar market access?
S. R. Mehr
Caring for communities: A 4-year pharmacy partnership focused on diabetes and cardiovascular health
W. Nuffer, A. Thompson, K. Stenhoff, and M. Bjork
Perspectives
The effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa
B. Herce-Hagiwara, A. McKenna, A. N. Makam, M. Richardson, W. Lee, M. Phillips, D. M. Rind, and F. Agboola
Supplements
Payer best practices in food allergy management
T. Richardson, S. Wescott, R. Gupta, R. Haumschild, M. Kobernick, J. Albright, M. Abdo, and J. Bioc
Impact of the evolving understanding of multiple sclerosis and emerging treatment approaches on managed care
B. Flavin, J. Bioc, J. Evans, R. Lich, T. O’Shea, and H. Pourarsalan
JMCP, August 2025, Volume 31, Number 8
Align your brand with 30 years of JMCP and advancing the conversation in managed care pharmacy. New advertising packages available through 2025 include:
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
